Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Melanoma

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 80 articles:
HTML format
Text format



Single Articles


    May 2019
  1. ANICHINI A
    Progress in Understanding Complexity and Determinants of Immune-Related Prognostic Subsets in Primary Melanoma.
    Cancer Res. 2019;79:2457-2459.
    PubMed     Text format     Abstract available


  2. YOO JH, Brady SW, Acosta-Alvarez L, Rogers A, et al
    The small GTPase ARF6 activates PI3K in melanoma to induce a pro-metastatic state.
    Cancer Res. 2019 May 2. pii: 0008-5472.CAN-18-3026.
    PubMed     Text format     Abstract available


    April 2019
  3. SHIDAL C, Singh NP, Nagarkatti P, Nagarkatti M, et al
    MicroRNA-92 expression in CD133+ melanoma stem cells regulates immunosuppression in the tumor microenvironment via integrin-dependent activation of TGF-beta.
    Cancer Res. 2019 Apr 23. pii: 0008-5472.CAN-18-2659.
    PubMed     Text format     Abstract available


  4. EMMONS MF, Faiao-Flores F, Sharma R, Thapa R, et al
    HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy.
    Cancer Res. 2019 Apr 15. pii: 0008-5472.CAN-19-0040.
    PubMed     Text format     Abstract available


  5. SHAH R, Singh SJ, Eddy K, Filipp FV, et al
    Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1(+) Melanoma.
    Cancer Res. 2019;79:1799-1809.
    PubMed     Text format     Abstract available


    March 2019
  6. SHURIN GV, Kruglov O, Ding F, Lin Y, et al
    Melanoma-induced reprogramming of Schwann cell signaling aids tumor growth.
    Cancer Res. 2019 Mar 26. pii: 0008-5472.CAN-18-3872.
    PubMed     Text format     Abstract available


  7. REVACH OY, Sandler O, Samuels Y, Geiger B, et al
    Cross-talk between receptor tyrosine kinases AXL and ERBB3 regulates invadopodia formation in melanoma cells.
    Cancer Res. 2019 Mar 26. pii: 0008-5472.CAN-18-2316.
    PubMed     Text format     Abstract available


  8. KIM E, Zucconi BE, Wu M, Nocco SE, et al
    MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma.
    Cancer Res. 2019 Mar 25. pii: 0008-5472.CAN-18-2331.
    PubMed     Text format     Abstract available


  9. AMBROSINI G, Do C, Tycko B, Realubit RB, et al
    Inhibition of NF-kappaB-dependent signaling enhances sensitivity and overcomes resistance to BET inhibition in uveal melanoma.
    Cancer Res. 2019 Mar 18. pii: 0008-5472.CAN-18-3177.
    PubMed     Text format     Abstract available


  10. BENITO-JARDON L, Diaz-Martinez M, Arellano-Sanchez N, Vaquero-Morales P, et al
    Resistance to MAPK inhibitors in melanoma involves activation of the IGF-1R-MEK5-Erk5 pathway.
    Cancer Res. 2019 Mar 4. pii: 0008-5472.CAN-18-2762.
    PubMed     Text format     Abstract available


    February 2019
  11. HAYES TK, Luo F, Cohen O, Goodale AB, et al
    A functional landscape of resistance to MEK1/2 and CDK4/6 inhibition in NRAS mutant melanoma.
    Cancer Res. 2019 Feb 28. pii: 0008-5472.CAN-18-2711.
    PubMed     Text format     Abstract available


  12. TURANI Z, Fatemizadeh E, Blumetti T, Daveluy S, et al
    Optical Radiomic Signatures Derived from Optical Coherence Tomography Images to Improve Identification of Melanoma.
    Cancer Res. 2019 Feb 18. pii: 0008-5472.CAN-18-2791.
    PubMed     Text format     Abstract available


  13. POZNIAK J, Nsengimana J, Laye JP, O'Shea SJ, et al
    Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma.
    Cancer Res. 2019 Feb 17. pii: 0008-5472.CAN-18-2864.
    PubMed     Text format     Abstract available


    January 2019
  14. SHIELDS BD, Koss B, Taylor EM, Storey AJ, et al
    Loss of E-cadherin inhibits CD103 anti-tumor activity and reduces checkpoint blockade responsiveness in melanoma.
    Cancer Res. 2019 Jan 23. pii: 0008-5472.CAN-18-1722.
    PubMed     Text format     Abstract available


  15. FORSBERG EM, Lindberg MF, Jespersen H, Alsen S, et al
    HER2 CAR-T cells eradicate uveal melanoma and T cell therapy-resistant human melanoma in interleukin-2 (IL-2) transgenic NOD/SCID IL-2 receptor knockout mice.
    Cancer Res. 2019 Jan 8. pii: 0008-5472.CAN-18-3158.
    PubMed     Text format     Abstract available


    December 2018
  16. BONVIN E, Radaelli E, Bizet M, Luciani F, et al
    Tet2-dependent hydroxymethylome plasticity reduces melanoma initiation and progression.
    Cancer Res. 2018 Dec 11. pii: 0008-5472.CAN-18-1214.
    PubMed     Text format     Abstract available


    November 2018
  17. MASTROIANNI J, Stickel N, Andrlova H, Hanke K, et al
    miR-146a controls immune response in the melanoma microenvironment.
    Cancer Res. 2018 Nov 13. pii: 0008-5472.CAN-18-1397.
    PubMed     Text format     Abstract available


    October 2018
  18. RAVINDRAN MENON D, Luo Y, Arcaroli JJ, Liu S, et al
    CDK1 interacts with Sox2 and promotes tumor initiation in human melanoma.
    Cancer Res. 2018 Oct 8. pii: 0008-5472.CAN-18-0330.
    PubMed     Text format     Abstract available


    September 2018
  19. DIKSHIT A, Jin YJ, Degan S, Hwang J, et al
    UBE2N promotes melanoma growth via MEK/FRA1/SOX10 signaling.
    Cancer Res. 2018 Sep 17. pii: 0008-5472.CAN-18-1040.
    PubMed     Text format     Abstract available


  20. PICH C, Meylan P, Mastelic-Gavillet B, Nguyen NT, et al
    Induction of paracrine signaling in metastatic melanoma cells by PPARgamma agonist rosiglitazone activates stromal cells and enhances tumor growth.
    Cancer Res. 2018 Sep 5. pii: 0008-5472.CAN-18-0912.
    PubMed     Text format     Abstract available


    August 2018
  21. THRANE K, Eriksson H, Maaskola J, Hansson J, et al
    Spatially resolved transcriptomics enables dissection of genetic heterogeneity in stage III cutaneous malignant melanoma.
    Cancer Res. 2018 Aug 28. pii: 0008-5472.CAN-18-0747.
    PubMed     Text format     Abstract available


  22. CAPPARELLI C, Purwin TJ, Heilman SA, Chervoneva I, et al
    ErbB3 targeting enhances the effects of MEK inhibitor in wild-type BRAF/NRAS melanoma.
    Cancer Res. 2018 Aug 16. pii: 0008-5472.CAN-18-1001.
    PubMed     Text format     Abstract available


  23. HUANG M, Qi TF, Li L, Zhang G, et al
    A targeted quantitative proteomic approach assesses the reprogramming of small GTPases during melanoma metastasis.
    Cancer Res. 2018 Aug 2. pii: 0008-5472.CAN-17-3811.
    PubMed     Text format     Abstract available


    July 2018
  24. VISHNOI M, Boral D, Liu H, Sprouse ML, et al
    Targeting USP7 identifies a metastasis-competent state within bone marrow-resident melanoma CTCs.
    Cancer Res. 2018 Jul 19. pii: 0008-5472.CAN-18-0644.
    PubMed     Text format     Abstract available


  25. SHABANEH TB, Molodtsov A, Steinberg SM, Zhang P, et al
    Oncogenic BRAFV600E governs regulatory T cell recruitment during melanoma tumorigenesis.
    Cancer Res. 2018 Jul 19. pii: 0008-5472.CAN-18-0365.
    PubMed     Text format     Abstract available


    June 2018
  26. WANG L, Felts SJ, Van Keulen VP, Scheid AD, et al
    Integrative genome-wide analysis of long noncoding RNAs in diverse immune cell types of melanoma patients.
    Cancer Res. 2018 Jun 12. pii: 0008-5472.CAN-18-0529.
    PubMed     Text format     Abstract available


    May 2018
  27. HUERGO ZAPICO L, Parodi M, Cantoni C, Lavarello C, et al
    NK cell editing mediates Epithelial to Mesenchymal Transition via phenotypic and proteomic changes in melanoma cell lines.
    Cancer Res. 2018 May 11. pii: 0008-5472.CAN-17-1891.
    PubMed     Text format     Abstract available


    February 2018
  28. YOUNG A, Ngiow SF, Gao Y, Patch AM, et al
    A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.
    Cancer Res. 2018;78:1003-1016.
    PubMed     Text format     Abstract available


  29. HOULES T, Gravel SP, Lavoie G, Shin S, et al
    RSK Regulates PFK-2 Activity to Promote Metabolic Rewiring in Melanoma.
    Cancer Res. 2018 Feb 12. pii: 0008-5472.CAN-17-2215.
    PubMed     Text format     Abstract available


  30. TAYLOR A, Rothstein D, Rudd CE
    Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy.
    Cancer Res. 2018;78:706-717.
    PubMed     Text format     Abstract available


    January 2018
  31. CAUWELS A, Van Lint S, Paul F, Garcin G, et al
    Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments.
    Cancer Res. 2018;78:463-474.
    PubMed     Text format     Abstract available


  32. ARNST KE, Wang Y, Hwang DJ, Xue Y, et al
    A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
    Cancer Res. 2018;78:265-277.
    PubMed     Text format     Abstract available


  33. CANALE FP, Ramello MC, Nunez N, Araujo Furlan CL, et al
    CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8(+) T Cells.
    Cancer Res. 2018;78:115-128.
    PubMed     Text format     Abstract available


    December 2017
  34. SIMON S, Vignard V, Varey E, Parrot T, et al
    Emergence of High-Avidity Melan-A-Specific Clonotypes as a Reflection of Anti-PD-1 Clinical Efficacy.
    Cancer Res. 2017;77:7083-7093.
    PubMed     Text format     Abstract available


  35. DIAZ-MARTINEZ M, Benito-Jardon L, Alonso L, Koetz-Ploch L, et al
    miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma.
    Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1318.
    PubMed     Text format     Abstract available


  36. YAEGER R, Yao Z, Hyman DM, Hechtman JF, et al
    Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.
    Cancer Res. 2017;77:6513-6523.
    PubMed     Text format     Abstract available


    November 2017
  37. WANG G, Mustafi S, Camarena V, Volmar CH, et al
    Vitamin C sensitizes melanoma to BET inhibitors.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-2040.
    PubMed     Text format     Abstract available


  38. BRIGHTON HE, Angus SP, Bo T, Roques J, et al
    New mechanisms of resistance to MEK inhibitors in melanoma revealed by intravital imaging.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1653.
    PubMed     Text format     Abstract available


  39. MO X, Zhang H, Preston S, Martin K, et al
    Interferon-2; signaling in melanocytes and melanoma cells regulates expression of CTLA-4.
    Cancer Res. 2017 Nov 17. pii: canres.1615.2017.
    PubMed     Text format     Abstract available


  40. HUA KT, Hong JB, Sheen YS, Huang HY, et al
    MicroRNA-519d promotes melanoma progression by downregulating EphA4.
    Cancer Res. 2017 Nov 1. pii: canres.1933.2017.
    PubMed     Text format     Abstract available


    October 2017
  41. BLATTNER C, Fleming V, Weber R, Himmelhan BS, et al
    CCR5+ myeloid-derived suppressor cells are enriched and activated in melanoma lesions.
    Cancer Res. 2017 Oct 31. pii: canres.0348.2017.
    PubMed     Text format     Abstract available


  42. SIERRA RA, Trillo-Tinoco J, Mohamed E, Yu L, et al
    Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance.
    Cancer Res. 2017;77:5628-5638.
    PubMed     Text format     Abstract available


  43. BUCSEK MJ, Qiao G, MacDonald CR, Giridharan T, et al
    beta-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy.
    Cancer Res. 2017;77:5639-5651.
    PubMed     Text format     Abstract available


  44. COUNTER CM, Crowe MS, Greenberg DN, Brady DC, et al
    Copper Chelation Inhibits BRAFV600E-driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors.
    Cancer Res. 2017 Oct 6. pii: canres.1190.2016.
    PubMed     Text format     Abstract available


  45. PICCO N, Sahai E, Maini PK, Anderson ARA, et al
    Integrating Models to Quantify Environment-Mediated Drug Resistance.
    Cancer Res. 2017;77:5409-5418.
    PubMed     Text format     Abstract available


    September 2017
  46. LI J, Yan S, Liu Z, Zhou Y, et al
    Multiregional sequencing reveals genomic alterations and clonal dynamics in primary malignant melanoma of the esophagus.
    Cancer Res. 2017 Sep 29. pii: canres.0938.2017.
    PubMed     Text format     Abstract available


  47. WANG JY, Liu GZ, Wilmott JS, La T, et al
    Skp2-mediated stabilization of MTH1 promotes survival of melanoma cells upon oxidative stress.
    Cancer Res. 2017 Sep 25. pii: canres.1965.2017.
    PubMed     Text format     Abstract available


  48. NEISWENDER JV, Kortum RL, Bourque C, Kasheta M, et al
    KIT suppresses BRAFV600E-mutant melanoma by attenuating oncogenic RAS/MAPK signaling.
    Cancer Res. 2017 Sep 25. pii: canres.0473.2017.
    PubMed     Text format     Abstract available


  49. LI P, Wuthrick E, Rappaport JA, Kraft C, et al
    GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.
    Cancer Res. 2017;77:5095-5106.
    PubMed     Text format     Abstract available


  50. NDOYE A, Budina-Kolomets A, Kugel CH, Webster MR, et al
    ATG5 mediates a positive feedback loop between Wnt signaling and autophagy in melanoma.
    Cancer Res. 2017 Sep 8. pii: canres.0907.2017.
    PubMed     Text format     Abstract available


  51. DONIA M, Harbst K, van Buuren M, Kvistborg P, et al
    Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNgamma Signaling.
    Cancer Res. 2017;77:4562-4566.
    PubMed     Text format     Abstract available


    August 2017
  52. YANG F, Wei J, Zhang S, Zhang X, et al
    Shrimp miR-S8 suppresses the stemness of human melanoma stem-like cells by targeting the transcription factor YB-1.
    Cancer Res. 2017 Aug 30. pii: canres.1375.2017.
    PubMed     Text format     Abstract available


  53. ZHAO Y, Ting KK, Li J, Cogger VC, et al
    Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy.
    Cancer Res. 2017;77:4434-4447.
    PubMed     Text format     Abstract available


  54. ABU EID R, Ahmad S, Lin Y, Webb M, et al
    Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-delta Inhibition.
    Cancer Res. 2017;77:4135-4145.
    PubMed     Text format     Abstract available


    July 2017
  55. JIANG H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, et al
    Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.
    Cancer Res. 2017;77:3894-3907.
    PubMed     Text format     Abstract available



  56. Retraction: Molecular Mechanism of MART-1+/A*0201+ Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor-CTL Interaction.
    Cancer Res. 2017;77:3718.
    PubMed     Text format    


  57. FERNANDEZ-POMA SM, Salas-Benito D, Lozano T, Casares N, et al
    Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.
    Cancer Res. 2017;77:3672-3684.
    PubMed     Text format     Abstract available


    June 2017
  58. REINHARDT J, Landsberg J, Schmid-Burgk JL, Bibiloni Ramis B, et al
    MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy.
    Cancer Res. 2017 Jun 26. pii: canres.0395.2017.
    PubMed     Text format     Abstract available


  59. YOUNG A, Ngiow SF, Madore J, Reinhardt J, et al
    Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis.
    Cancer Res. 2017 Jun 26. pii: canres.0393.2017.
    PubMed     Text format     Abstract available


  60. BARTEE MY, Dunlap KM, Bartee E
    Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy.
    Cancer Res. 2017;77:2952-2963.
    PubMed     Text format     Abstract available


    May 2017

  61. Correction: Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
    Cancer Res. 2017;77:2770.
    PubMed     Text format    


  62. PRAT A, Navarro A, Pare L, Reguart N, et al
    Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma and melanoma.
    Cancer Res. 2017 May 9. pii: canres.3556.2017.
    PubMed     Text format     Abstract available


  63. LARIMER BM, Wehrenberg-Klee E, Dubois F, Mehta A, et al
    Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.
    Cancer Res. 2017;77:2318-2327.
    PubMed     Text format     Abstract available


  64. GUO G, Yu M, Xiao W, Celis E, et al
    Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity.
    Cancer Res. 2017;77:2292-2305.
    PubMed     Text format     Abstract available


    April 2017
  65. NIMANONG S, Ostroumov D, Wingerath J, Knocke S, et al
    CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations.
    Cancer Res. 2017;77:1918-1926.
    PubMed     Text format     Abstract available


    March 2017

  66. Correction: Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E.
    Cancer Res. 2017;77:1505.
    PubMed     Text format    


  67. KIRTANE AR, Sadhukha T, Kim H, Khanna V, et al
    Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine.
    Cancer Res. 2017;77:1465-1475.
    PubMed     Text format     Abstract available


  68. MAHNE AE, Mauze S, Joyce-Shaikh B, Xia J, et al
    Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
    Cancer Res. 2017;77:1108-1118.
    PubMed     Text format     Abstract available


    February 2017
  69. STEINBERG SM, Shabaneh T, Zhang P, Martyanov V, et al
    Myeloid cells that impair immunotherapy are restored in melanomas which acquire resistance to BRAF inhibitors.
    Cancer Res. 2017 Feb 15. pii: canres.1755.2016.
    PubMed     Text format     Abstract available


    January 2017
  70. ZHANG T, Xu M, Makowski MM, Lee C, et al
    SDHD promoter mutations ablate GABP transcription factor binding in melanoma.
    Cancer Res. 2017 Jan 20. pii: canres.0919.2016.
    PubMed     Text format     Abstract available


  71. NEUBERT NJ, Tille L, Barras D, Soneson C, et al
    Broad and conserved immune regulation by genetically heterogeneous melanoma cells.
    Cancer Res. 2017 Jan 19. pii: canres.2680.2016.
    PubMed     Text format     Abstract available


  72. SEKTIOGLU IM, Carretero R, Bulbuc N, Bald T, et al
    Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8+ T Cells.
    Cancer Res. 2017;77:291-302.
    PubMed     Text format     Abstract available


    November 2016
  73. JOYCE CE, Yanez AG, Mori A, Yoda A, et al
    Differential regulation of the melanoma proteome by eIF4A1 and eIF4E.
    Cancer Res. 2016 Nov 22. pii: canres.1298.2016.
    PubMed     Text format     Abstract available


    September 2016
  74. XIA T, Konno H, Barber GN
    Recurrent loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis.
    Cancer Res. 2016 Sep 28. pii: canres.1404.2016.
    PubMed     Text format     Abstract available


  75. KIM M, Neznanov N, Wilfong CD, Fleyshman DI, et al
    Preclinical validation of a single-treatment infusion modality that can eradicate extremity melanomas.
    Cancer Res. 2016 Sep 28. pii: canres.2764.2015.
    PubMed     Text format     Abstract available


  76. SATOW R, Nakamura T, Kato C, Endo M, et al
    ZIC5 drives melanoma aggressiveness by PDGFD-mediated activation of FAK and STAT3.
    Cancer Res. 2016 Sep 26. pii: canres.0991.2016.
    PubMed     Text format     Abstract available


  77. CLARK CA, Gupta H, Sareddy GR, Pandeswara S, et al
    Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis and autophagy in ovarian cancer and melanoma.
    Cancer Res. 2016 Sep 26. pii: canres.0258.2016.
    PubMed     Text format     Abstract available


  78. KLARQUIST J, Tobin K, Farhangi Oskuei P, Henning SW, et al
    CCL22 DIVERTS T REGULATORY CELLS AND CONTROLS THE GROWTH OF MELANOMA.
    Cancer Res. 2016 Sep 12. pii: canres.0618.2016.
    PubMed     Text format     Abstract available


    June 2016
  79. HU Y, Lu L, Xia Y, Chen X, et al
    Therapeutic efficacy of cancer stem cell vaccines in the adjuvant setting.
    Cancer Res. 2016 Jun 20. pii: canres.2664.2015.
    PubMed     Text format     Abstract available


    April 2016
  80. MENGER L, Sledzinska A, Bergerhoff K, Vargas FA, et al
    TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors.
    Cancer Res. 2016;76:2087-93.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: